US74366E1029
© ACCESSWIRE
07.01.2026
PTGX
LISTED
NASDAQ
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
News Preview
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026 in San Francisc...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
27.11.2025
PTGX
LISTED
NASDAQ
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
News Preview
NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications Staff (the "Staff") indicating that the Company is not in compliance with Nasdaq Listing Rules 5550(b)(1) (minimum stoc...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.11.2025
PTGX
LISTED
NASDAQ
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was submitted in SeptemberRusfertide granted breakthrough designation for patients in Polycythemia Vera (PV) and the subject of four presentations includin...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© ACCESSWIRE
03.11.2025
PTGX
LISTED
NASDAQ
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
News Preview
NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the Phase 3 VERIFY study, will be the focus of four presentations at the 67th Annual American Society of Hematology (ASH) Annual Meet...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESSWIRE
27.10.2025
PTGX
LISTED
NASDAQ
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
News Preview
Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus placeboUpdated ANTHEM-UC data support Phase 3 clinical development of icotrokinra in both moderately to severely active ulcerati...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.10.2025
PTGX
LISTED
NASDAQ
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
News Preview
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose at Week 12 in the Phase 2b ANTHEM-UC studyThese data support the promise of a first-in-class targeted oral peptide that selectively blocks the IL-23...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.09.2025
PTGX
LISTED
NASDAQ
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
News Preview
Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studiesIcotrokinra also showed sustained skin clearance and favorable safety profile in both adults and adolescents at Week 52 in Phase 3 ICONIC-LEAD studyPreclinical proof-of-concept d...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.09.2025
PTGX
LISTED
NASDAQ
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
News Preview
NEWARK, CALIFORNIA / ACCESS Newswire / September 15, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in ulcerative colitis will be the focus of a brief oral presentation at the United European Gastroenterology Week 2025 being held in Be...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.09.2025
PTGX
LISTED
NASDAQ
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
News Preview
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3 studies that met all primary and co-primary endpoints. This unprecedented data package includes head-to-head superiority comparisons versus deucravacitinib, adolescent data, and evaluation of difficult to tr...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
26.08.2025
PTGX
LISTED
NASDAQ
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
News Preview
NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in multiple investment bank conferences taking place in September.Citi's 2025 Biopharma Back to School Summi...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
25.08.2025
PTGX
LISTED
NASDAQ
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
News Preview
Breakthrough Therapy designation complements Rusfertide's Orphan Drug and Fast Track designations, which together confer multiple benefits to the development programU.S. New Drug Application filing for Rusfertide in polycythemia vera on track for Q4 NEWARK, CA / ACCESS Newswire / August 25, 2025 / Protagonist Therapeutics, Inc. ("Protagonist&q...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.08.2025
PTGX
LISTED
NASDAQ
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
News Preview
NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in JulyANTHEM Phase 2b trial data of icotrokinra in ulcerative colitis scheduled for an oral presentation at the 33rd United European Gastroenterology Week (UEGW) on October 7thPhase 3 VERIFY...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESSWIRE
21.07.2025
PTGX
LISTED
NASDAQ
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
News Preview
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptorFiling based on unprecedented data package that met all primary endpoints across four Phase 3 studies, including head-to-head superiority comparisons versus deucravacitinib and evaluation of difficult to treat skin sitesSubmission undersc...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.06.2025
PTGX
LISTED
NASDAQ
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
News Preview
A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptorsCompany will also develop a subcutaneous version, PN-477sc, as a once-weekly injectionIND-enabling studies underway, with Phase I study initiation expected i...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
26.06.2025
PTGX
LISTED
NASDAQ
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
News Preview
Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development cand...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
21.05.2025
PTGX
LISTED
NASDAQ
Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025
News Preview
NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare Conference taking place June 3-5, 2025, in New York, NY. The Company...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
09.05.2025
PTGX
LISTED
NASDAQ
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
News Preview
Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pillPN-881, a first-in-class oral p...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.05.2025
PTGX
LISTED
NASDAQ
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
News Preview
Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1stConference call to be held June 2nd at 8AM EDT to discuss rusfertide data presented at ASCOFull dataset from Phase 3 ICONIC-LEAD trial with icotrokinra in patients wit...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
23.04.2025
PTGX
LISTED
NASDAQ
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
News Preview
NEWARK, CA / ACCESS Newswire / April 23, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that an abstract was accepted for presentation at the Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 - June 3, 2025.Presentation Details:Presenting Author...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
16.04.2025
PTGX
LISTED
NASDAQ
Protagonist Therapeutics Reports Granting of Inducement Award
News Preview
NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced that on April 15, 2025 (the "Grant Date"), it issued an equity inducement aw...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
10.04.2025
PTGX
LISTED
NASDAQ
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
News Preview
84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16ICONIC-LEAD is the first ever Phase 3 registrational study in moderate-to-severe plaque psoriasis to assess safety and efficacy of a systemic therapy in adolescents and adults simultaneously NE...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.03.2025
PTGX
LISTED
NASDAQ
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
News Preview
Past Winners include Waymo, Nvidia, Duolingo, and Novo Nordisk, among others NEWARK, CALIFORNIA / ACCESS Newswire / March 18, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based therapeutics, today announced i...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
10.03.2025
PTGX
LISTED
NASDAQ
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
News Preview
Clinical response rate of 63.5% and clinical remission rate of 30.2% achieved at Week 12 with the highest dose, which continued to improve through Week 28All three doses met the primary endpoint of clinical response at Week 12, with a favorable safety profileThese results in ulcerative colitis build on strong data recently reported for the plaque p...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
08.03.2025
PTGX
LISTED
NASDAQ
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
News Preview
Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD studyTopline results from Phase 3 ICONIC-ADVANCE 1&2studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe PsORes...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
21.02.2025
PTGX
LISTED
NASDAQ
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
News Preview
$165.0 million icotrokinra (formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate in Q4 2024Topline results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in March 2025Topline results for icotro...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.01.2025
PTGX
LISTED
NASDAQ
Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025
News Preview
NEWARK, CALIFORNIA / ACCESS Newswire / January 29, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company")will host an in-person and virtual investor event on Thursday, February 6, 2025, at 10:30 AM ET in New York. To register, click here.The event will feature key opinion leader (KOL) insights from Andrew Kuykend...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.01.2025
PTGX
LISTED
NASDAQ
Protagonist Therapeutics Reports Granting of Inducement Awards
News Preview
NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment to the role of Executive Vice President, Chief Scientific Officer, in accordance with the terms of his employment offer letter. Dr. Yeildi...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.12.2024
PTGX
LISTED
NASDAQ
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
News Preview
NEWARK, CA / ACCESSWIRE / December 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a company overview at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 12-16, 2025 in San Francisco,...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
09.12.2024
PTGX
LISTED
NASDAQ
Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
News Preview
54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and improvements in patient-reported outcomes in patients with polycythemia vera NEWARK, CA / ACCESSWIRE / December 9, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company&qu...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
22.11.2024
PTGX
LISTED
NASDAQ
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
News Preview
NEWARK, CA / ACCESSWIRE / November 22, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference taking place December 3-5, 2024 in Coral Gables...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
21.11.2024
PTGX
LISTED
NASDAQ
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
News Preview
Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF and FF)IND enabling studies underway, with Phase I initiation expected in Q425Webcast and conference call to be held today at 4:30 pm ET NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics,...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.11.2024
PTGX
LISTED
NASDAQ
Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
News Preview
Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information belowNEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 ant...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.11.2024
PTGX
LISTED
NASDAQ
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113), a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor in Plaque Psoriasis
News Preview
NEWARK, CA / ACCESSWIRE / November 18, 2024 / Protagonist announces positive topline results from Phase 3 ICONIC studies of icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor in plaque psoriasisICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.11.2024
PTGX
LISTED
NASDAQ
Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update
News Preview
Top line results for JNJ-2113 Phase 3 ICONIC-LEAD and Phase 3 ICONIC-TOTAL clinical trials in patients with moderate to severe psoriasis expected in Q4 2024Top line results for JNJ-2113 Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in Q1 2025Top line results for rusfertide Phase 3 VERIFY clinical trial in polycyth...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.11.2024
PTGX
LISTED
NASDAQ
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
News Preview
NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia vera will be the focus of a poster presentation at the 66th Annual American Society of Hematology (ASH) Annual Meeting being held in...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
29.10.2024
PTGX
LISTED
NASDAQ
Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
News Preview
NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) ("Protagenic Therapeutics" or the "Company"), a leader in biopharmaceutical innovation, announced today it has entered into a purchase agreement (the "Purchase Agreement") for the purchase and sale of an aggregate of 1,948,295 sh...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
